Prostate Cancer P D:恩扎鲁胺和醋酸阿比特龙相关的骨靶向治疗和骨骼相关事件

2020-09-20 AlexYang MedSci原创

在转移趋势抵抗性前列腺癌(mCRPC)的多种延长生命治疗方法的时代,为了预防骨骼相关事件(SREs)而起始抗吸收骨靶向治疗(BTT)的最佳时机和治疗持续时间尚不清楚。

在转移趋势抵抗性前列腺癌(mCRPC)的多种延长生命治疗方法的时代,为了预防骨骼相关事件(SREs)而起始抗吸收骨靶向治疗(BTT)的最佳时机和治疗持续时间尚不清楚。

最近,有研究人员评估了BTT使用的实践模式及其与临床结果的相关性,研究包括了2007年至2017年BM治疗的mCRPC患者回顾性队列。研究终点包括从CRPC诊断到SRE或OS发生的时间。研究总共鉴定了249名患者;随访时间中值为7.7(95%CI:5.7-10.2)年。在多变量分析中,诊断为mCRPC时有4个或更多BM的患者接受醋酸阿比特龙或恩杂鲁胺进行BTT作为一线治疗患者与从未接受BTT或二线接受BTT的患者相比,SRE发生的风险降低了42%(HR 0.58;95%CI:0.36-0.95)。在1-3 BM的患者中没有观察到上述情况。另外,在接受BTT的患者中,无论是否接受一线治疗,均未发现OS存在差异。此外,该研究由于是在单一机构进行的回顾性研究而受到限制。

骨相关事件因素的单变量和多变量分析

最后,研究人员指出,对于至少有4个BM的CRPC患者,早期使用抗吸收BTT联合延长生命的CRPC治疗,在SRE预防方面有潜在的益处。

原始出处:

Bradley McGregor, Li Zhang, Kathryn P. Gray et al. Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases. Prostate Cancer P D. Sep 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1791635, encodeId=b1241e91635eb, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Feb 05 09:21:04 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887710, encodeId=084788e710fa, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Wed Sep 23 16:28:53 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364657, encodeId=97c0136465ec3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Sep 22 03:21:04 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368435, encodeId=b60f136843592, content=<a href='/topic/show?id=b6f29563625' target=_blank style='color:#2F92EE;'>#醋酸阿比特龙#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95636, encryptionId=b6f29563625, topicName=醋酸阿比特龙)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Tue Sep 22 03:21:04 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602307, encodeId=f71a160230e65, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Sep 22 03:21:04 CST 2020, time=2020-09-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1791635, encodeId=b1241e91635eb, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Feb 05 09:21:04 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887710, encodeId=084788e710fa, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Wed Sep 23 16:28:53 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364657, encodeId=97c0136465ec3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Sep 22 03:21:04 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368435, encodeId=b60f136843592, content=<a href='/topic/show?id=b6f29563625' target=_blank style='color:#2F92EE;'>#醋酸阿比特龙#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95636, encryptionId=b6f29563625, topicName=醋酸阿比特龙)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Tue Sep 22 03:21:04 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602307, encodeId=f71a160230e65, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Sep 22 03:21:04 CST 2020, time=2020-09-22, status=1, ipAttribution=)]
    2020-09-23 ms3000000449926787

    阅读

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1791635, encodeId=b1241e91635eb, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Feb 05 09:21:04 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887710, encodeId=084788e710fa, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Wed Sep 23 16:28:53 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364657, encodeId=97c0136465ec3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Sep 22 03:21:04 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368435, encodeId=b60f136843592, content=<a href='/topic/show?id=b6f29563625' target=_blank style='color:#2F92EE;'>#醋酸阿比特龙#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95636, encryptionId=b6f29563625, topicName=醋酸阿比特龙)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Tue Sep 22 03:21:04 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602307, encodeId=f71a160230e65, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Sep 22 03:21:04 CST 2020, time=2020-09-22, status=1, ipAttribution=)]
    2020-09-22 lsndxfj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1791635, encodeId=b1241e91635eb, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Feb 05 09:21:04 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887710, encodeId=084788e710fa, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Wed Sep 23 16:28:53 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364657, encodeId=97c0136465ec3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Sep 22 03:21:04 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368435, encodeId=b60f136843592, content=<a href='/topic/show?id=b6f29563625' target=_blank style='color:#2F92EE;'>#醋酸阿比特龙#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95636, encryptionId=b6f29563625, topicName=醋酸阿比特龙)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Tue Sep 22 03:21:04 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602307, encodeId=f71a160230e65, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Sep 22 03:21:04 CST 2020, time=2020-09-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1791635, encodeId=b1241e91635eb, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Feb 05 09:21:04 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887710, encodeId=084788e710fa, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Wed Sep 23 16:28:53 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364657, encodeId=97c0136465ec3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Sep 22 03:21:04 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368435, encodeId=b60f136843592, content=<a href='/topic/show?id=b6f29563625' target=_blank style='color:#2F92EE;'>#醋酸阿比特龙#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95636, encryptionId=b6f29563625, topicName=醋酸阿比特龙)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Tue Sep 22 03:21:04 CST 2020, time=2020-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602307, encodeId=f71a160230e65, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Sep 22 03:21:04 CST 2020, time=2020-09-22, status=1, ipAttribution=)]
    2020-09-22 sunylz

相关资讯

Immunol Lett:过敏性鼻炎中Omalizumab的长期疗效如何?

在治疗不佳的重症哮喘患者中,Omalizumab作为附加疗法是安全和有效的。虽然在过去的十年中,有一些研究表明Omalizumab在其他免疫球蛋白E相关疾病中的疗效,但其在鼻炎和哮喘疾病中的使用仍旧未

Eur Respir J:肥胖和正常体重哮喘患者哮喘药物分析

尽管FEV1较低且FEV1/FVC%较低,肥胖的哮喘患者使用的哮喘药物种类和ICS剂量均高于正常体重的哮喘患者。需要更好地了解导致药物使用增加的因素,以改善哮喘亚组的预后。

J Inflamm Res:新研究鉴定了BX471对变应性鼻炎的治疗作用

变应性鼻炎(AR)是一种免疫球蛋白E (IgE)介导的炎症性呼吸过敏,其特征是Th2细胞因子升高和炎症细胞向鼻组织浸润。BX471是一种小分子C-C趋化因子受体1型(CCR1)拮抗剂,它通过阻断初级配

从入选主席研讨会到燃爆全球,听WCLC大会主席吴一龙教授谈胸膜间皮瘤治疗新突破

免疫治疗方案在经过不断地优化和调整后,在多个临床研究中均表现出高度的安全性。在该研究中,纳武利尤单抗联合伊匹木单抗的安全性与既往报道的研究结果一致,未观察到新的安全性信号。

广西一患者遵医嘱服用十倍药物后进ICU 医院致歉

针对“遵医嘱服用十倍药物后,患者昏迷进ICU”一事,9月17日下午,广西医科大学第二附属医院发布声明称,目前患者仍在医院接受康复治疗,各项指标已基本恢复至发病前状态,医院对该事

翰森制药:上半年收入净利润双降,1创新2首仿6款药物获批

亿欧大健康9月3日消息,翰森制药集团有限公司(以下简称“翰森制药”)近日发布其2020年中期业绩公告。上半年,翰森制药实现收入39.80亿元,同比下降13.5%,净利润12.2